A bipartisan group of U.S. senators recently sent a letter to Mark Esper, the secretary of defense, expressing concern over the national security risks posed by U.S. reliance on foreign-manufactured pharmaceutical products.
The letter is in response to the U.S.-China Economic and Security Review Commission’s 2019 annual report that highlighted the growth of foreign products in drug manufacturing.
China is the global leader for pharmaceutical products, especially active pharmaceutical ingredients (APIs) that are used to make vaccines and generic drugs. Only 20 percent of the APIs used in domestic pharmaceutical production are manufactured in the United States.
The senators pointed out that the Food and Drug Administration does not consistently conduct tests to verify the contents or quality of APIs or drugs that enter the United States and that the Department of Defense provides service members and their families with drugs that can contain ingredients from China.
“…overreliance on Chinese API exports raises the possibility that China could terminate or raise the cost of prescription drugs that millions of Americans, including service members, rely on every day in the event of escalating geopolitical tensions,” the letter said.
The letter was signed by Sens. Tom Cotton (R-AR), Tim Kaine (D-VA), Mitt Romney (R-UT), and Elizabeth Warren (D-MA).
The ByteDance-owned TikTok faces an uphill battle in the United States after President Joe Biden…
Promising to grow space for integrating and delivering on critical defense programs by more than…
In unsealing a 13-page indictment this week, the U.S. Department of Justice (DOJ) revealed charges…
A bill targeting the illicit fentanyl supply chain, the Fentanyl Eradication and Narcotics Deterrence (FEND)…
In order to move the state closer to federal standards and allow reporting of local…
For the next round of participants in a pilot program to Accelerate the Procurement and…
This website uses cookies.